Claims for Patent: 10,383,947

Summary for Patent: 10,383,947

Title:	Pharmaceuticals in joint-linker configurations for treating pathological blood clots
Abstract:	The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.
Inventor(s):	Chang; Tse-Wen (Taipei, TW), Chu; Hsing-Mao (Taipei, TW)
Assignee:	Immunwork Inc. (Taipei, TW)
Application Number:	15/212,301
Patent Claims:	1. A molecular construct comprising a first linker unit and a second linker unit, wherein, the first linker unit comprises, a first center core comprising a plurality of amine groups, a first linking arm linked to the first center core, a first element linked to the first linking arm, and optionally, a first coupling arm linked to the first center core; the second linker unit comprises, a second center core comprising a plurality of amine groups, a second linking arm linked to the second center core, a second element linked to the second linking arm, and optionally, a second coupling arm linked to the second center core; and the first and second linker units are coupled to each other via copper catalyzed azide-alkyne cycloaddition (CuAAC) reaction, strained-promoted azide-alkyne click chemistry (SPAAC) reaction or inverse electron demand Diels-Alder (iEDDA) reaction occurred between any of the followings: the first and second center cores, the first coupling arm and the second center core, the first and second coupling arms, or the first center core and the second coupling arm; wherein, the first or second center core is independently a polypeptide core or a compound core, wherein the polypeptide core comprises, (1) a plurality of lysine (K) residues, wherein each K residue and its next K residue are separated by a filler sequence comprising glycine (G) and serine (S) residues, and the number of K residues ranges from 2 to 15; or (2) the sequence of (Xaa-K)n, where Xaa is a PEGylated amino acid having 2 to 12 repeats of ethylene glycol (EG) unit, and n is an integer from 2 to 15; wherein at least one of the N- and C-terminal amino acid residues of the polypeptide is an amino acid having an azide or an alkyne group or is a cysteine residue, and when one of the N- and C-terminal amino acid residues is the cysteine residue, the linker unit further comprises, optionally, the coupling arm that is linked to the cysteine residue via the thiol group of the cysteine residue and has an azide, an alkyne, a tetrazine, a cyclooctene, or a cyclooctyne group at the free terminus thereof; and the compound core is selected from the group consisting of, benzene-1,3,5-triamine, 2-(aminomethyl)-2-methylpropane-1,3-diamine, tris(2-aminoethyl)amine, benzene-1,2,4,5-tetraamine, 3,3',5,5'-tetraamine-1,1'-biphenyl, tetrakis(2-aminoethyl)methane, tetrakis-(ethylamine)hydrazine, N,N,N',N'-tetrakis(aminoethyl)ethylenediamine, benzene-1,2,3,4,5,6-hexaamine, 1-N,1-N,3-N,3-N,5-N,5-N-hexakis(methylamine)-benzene-1,3,5-triamine, 1-N,1-N,2-N,2-N,4-N,4-N,5-N,5-N,-octakis(methylamine)-benzene-1,2,4,5-tri- amine, and N,N-bis[(1-amino-3,3-diaminoethyl)pentyl] methanediamine; and the first or second coupling arm linked to said compound core is linked thereto via forming an amide bond with one of the plurality of amine groups of the compound core and has an azide, an alkyne, a tetrazine, a cyclooctene, or a cyclooctyne group at the free-terminus thereof; the first and second linking arms are respectively linked to the amine groups of the first and second center cores via forming an amide bond; the first and second elements are respectively linked to the first and second linking arms via forming an amide bond, or via thiol-maleimide, CuAAC, iEDDA, or SPAAC reaction; and the first element is an scFv specific for fibrin, and the second element is a tissue plasminogen activator, an inhibitor of Factor Xa, or an inhibitor of thrombin. 2. The molecular construct of claim 1, wherein the first and second linker units respectively comprise a plurality of the first and second linking arms linked thereto. 3. The molecular construct of claim 2, further comprising a plurality of first and second elements respectively linked to the first and second linking arms. 4. The molecular construct of claim 1, wherein, each of the first and second linking arms is a PEG chain having 2-20 repeats of ethylene glycol (EG) units; and each of the first and second coupling arms is a PEG chain having 2-12 repeats of EG units. 5. The molecular construct of claim 1, wherein, one of the first and second coupling arms has the azide group at the free-terminus thereof, and the other of the first and second coupling arms has the alkyne or the cyclooctyne group at the free-terminus thereof; and the first and second linker units are coupled to each other via copper catalyzed azide-alkyne cycloaddition (CuAAC) reaction or strained-promoted azide-alkyne click chemistry (SPAAC) reaction occurred between the first and second coupling arms. 6. The molecular construct of claim 1, wherein the cyclooctyne group is dibenzocyclooctyne (DBCO), difluorinated cyclooctyne (DIFO), bicyclononyne (BCN), or dibenzocyclooctyne (DICO). 7. The molecular construct of claim 1, wherein, one of the first and second coupling arms has the tetrazine group at the free-terminus thereof, and the other of the first and second coupling arms has the cyclooctene group at the free-terminus thereof; and the first and second linker units are coupled to each other via iEDDA reaction occurred between the first and second coupling arms. 8. The molecular construct of claim 1, wherein the tetrazine group is 1,2,3,4-tetrazine, 1,2,3,5-tetrazine or 1,2,4,5-tetrazine, or derivatives thereof. 9. The molecular construct of claim 1, wherein one of the first and the second center cores is the compound core. 10. The molecular construct of claim 1, wherein, one of the first and the second center cores is the compound core, and the coupling arm linked to the compound core has a DBCO, a DIFO, a BCN, or a DICO group at the free-terminus thereof; the other of the first and the second center cores is the polypeptide core in which the N- or C-terminal amino acid residue is L-azidohomoalanine (AHA), 4-azido-L-phenylalanine, 4-azido-D-phenylalanine, 3-azido-L-alanine, 3-azido-D-alanine, 4-azido-L-homoalanine, 4-azido-D-homoalanine, 5-azido-L-ornithine, 5-azido-d-ornithine, 6-azido-L-lysine, or 6-azido-D-lysine; and the first and second linker units are coupled to each other via SPAAC reaction occurred between the coupling arm and the N- or C-terminal amino acid residue. 11. The molecular construct of claim 1, wherein at least one of the first and second center cores is the polypeptide core. 12. The molecular construct of claim 1, wherein the filler sequence has the sequence of GS, GGS, GSG, or SEQ ID NOs: 1-16. 13. The molecular construct of claim 1, wherein the polypeptide core comprises 2-15 units of the sequence of G.sub.1-5SK. 14. The molecular construct of claim 13, wherein the polypeptide core comprises the sequence of (GSK).sub.2-15. 15. The molecular construct of claim 1, wherein the first and second center cores are independently the polypeptide cores. 16. The molecular construct of claim 15, wherein the N-terminus of each of the first and second center cores is modified with an acetyl group. 17. The molecular construct of claim 15, wherein, the N- or C-terminal amino acid residue of one of the first and second center cores is AHA, 4-azido-L-phenylalanine, 4-azido-D-phenylalanine, 3-azido-L-alanine, 3-azido-D-alanine, 4-azido-L-homoalanine, 4-azido-D-homoalanine, 5-azido-L-ornithine, 5-azido-d-ornithine, 6-azido-L-lysine, or 6-azido-D-lysine; the N- or C-terminal amino acid residue of the other of the first and second center cores is L-homopropargylglycine (L-HPG), D-homopropargylglycine (D-HPG), or beta-homopropargylglycine (.beta.-HPG); and the first and second center cores are coupled to each other via copper catalyzed azide-alkyne cycloaddition (CuAAC) reaction occurred between the N- or C-terminal amino acid residues. 18. The molecular construct of claim 15, wherein each of the first and second center cores comprises a cysteine residue at the N- or C-terminus thereof. 19. The molecular construct of claim 15, wherein, the N- or C-terminal amino acid residue of one of the first and second center cores is AHA, 4-azido-L-phenylalanine, 4-azido-D-phenylalanine, 3-azido-L-alanine, 3-azido-D-alanine, 4-azido-L-homoalanine, 4-azido-D-homoalanine, 5-azido-L-ornithine, 5-azido-d-ornithine, 6-azido-L-lysine, or 6-azido-D-lysine; the N- or C-terminal amino acid residue of the other of the first and second center cores is a cysteine residue, and the coupling arm has a DBCO, a DIFO, a BCN, or a DICO group at the free-terminus thereof; and the first and second center cores are coupled to each other via SPAAC reaction occurred between the N- or C-terminal amino acid residue and the coupling arm. 20. The molecular construct of claim 1, wherein the tissue plasminogen activator is alteplase, reteplase, tenecteplase, or lanoteplase. 21. The molecular construct of claim 1, wherein the inhibitor of Factor Xa is apixaban, edoxaban, or rivaroxaban; and the inhibitor of thrombin is argatroban or melagatran. 22. The molecular construct of claim 1, further comprising a third linking arm linked to the first or the second linker unit. 23. The molecular construct of claim 22, wherein the third linking arm has a maleimide group at the free terminus thereof, and a third element is linked to the third linking arm via thiol-maleimide reaction. 24. The molecular construct of claim 23, wherein the third element is different from the first element and the second element. 25. The molecular construct of claim 24, wherein the third element is a long PEG chain having a molecular weight of about 20,000 to 50,000 Daltons.

Details for Patent 10,383,947

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2039-08-20
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2039-08-20
Chiesi Usa, Inc.	RETAVASE	reteplase	For Injection	103786	10/30/1996		2039-08-20